Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | XN575 | OT / RA |
54-year-old male patient coming into the hospital after a traumatic fall off a ladder at work. Patient was seen in the hospital emergency department and received fentanyl 50 mcg for pain management and iohexol for contrast for CT imaging. After imaging, Tdap vaccine (Boostrix) was given by RN for tetanus prophylaxis as patient had unknown Tdap vaccine history. RN reports giving Tdap via intravenous route instead of intramuscular route after administration. Poison Control Center was contacted. Discussed concerns for possible anaphylaxis reaction when administering Tdap via intravenous route based on prior literature with patient. Patient was monitored for 3 hours after Tdap administration without any reports of adverse reactions. Pharmacist, RN, and MD were at bedside to discuss anaphylaxis symptoms and return precautions.
None
None
None